Your browser doesn't support javascript.
loading
Prognosis of Patients with Cutaneous Angiosarcoma After Surgical Resection with Curative Intent: Is There a Difference Between the Subtypes?
Reijers, Sophie J M; Huis In 't Veld, Eva A; Grünhagen, Dirk J; Smith, Myles J F; van Ginhoven, Tessa M; van Coevorden, Frits; van der Graaf, Winette T A; Schrage, Yvonne; Strauss, Dirk C; Haas, Rick L M; Verhoef, Cornelis J; Hayes, Andrew J; van Houdt, Winan J.
  • Reijers SJM; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Huis In 't Veld EA; Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Grünhagen DJ; Department of Surgical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Smith MJF; Department of Surgical Oncology, Royal Marsden Hospital, London, UK.
  • van Ginhoven TM; Department of Surgical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • van Coevorden F; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Graaf WTA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Schrage Y; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Strauss DC; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Haas RLM; Department of Surgical Oncology, Royal Marsden Hospital, London, UK.
  • Verhoef CJ; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Hayes AJ; Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • van Houdt WJ; Department of Surgical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
Ann Surg Oncol ; 30(1): 493-502, 2023 Jan.
Article en En | MEDLINE | ID: mdl-36209324
ABSTRACT

BACKGROUND:

The etiology of cutaneous angiosarcoma (cAS) may be idiopathic (I-cAS), or arise secondary to radiotherapy (RT-cAS), in chronic lymphedema (ST-cAS), or related to UV exposure (UV-cAS). The aim of this study was to evaluate oncological outcomes of different cAS subtypes. PATIENTS AND

METHODS:

Non-metastatic cAS patients, treated with surgery for primary disease with curative intent, were retrospectively analyzed for oncological outcome, including local recurrence (LR), distant metastases (DM), and overall survival (OS).

RESULTS:

A total of 234 patients were identified; 60 I-cAS, 122 RT-cAS, 9 ST-cAS, and 43 UV-cAS. The majority was female (78%), the median age was 66 years (IQR 57-76 years), the median tumor size was 4.4 cm (IQR 2.5-7.0 cm), and most common site of disease was the breast (59%). Recurrence was identified in 66% (44% LR and/or 41% DM), with a median follow up of 26.5 months (IQR 12-60 months). The 5-year OS was estimated at 50%, LRFS at 47%, and DMFS at 50%. There was no significant difference in LR, DM, or OS between the subtypes. Age < 65 years and administration of radiotherapy (RT) were significantly associated with lower LR rates (HR 0.560, 95% CI 0.3373-0.840, p = 0.005 and HR 0.421, 95% CI 0.225-0.790, p = 0.007, respectively), however no prognostic factors were identified for development of DM. Development of DM, but not LR (p = 0.052), was significantly associated with decreased OS (HR 6.486, 95% CI 2.939-14.318 p < 0.001).

CONCLUSION:

We found no significant difference in oncological outcome between the different cAS subtypes. OS remains relatively poor, and RT is associated with lower LR rates.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hemangiosarcoma Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hemangiosarcoma Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2023 Tipo del documento: Article